RxBio
RxBio, based in Johnson City, TN, develops proprietary medications for health issues like Acute Radiation Syndrome and secretory diarrhea, with its lead product, Rx100, showing promise in multiple animal models.
Company Overview
RxBio is a pharmaceutical company based in Johnson City, TN, specializing in the development of novel and proprietary medications for various health issues including Acute Radiation Syndrome (ARS) and secretory diarrhea. The company focuses on the discovery and development of compounds for mitigating acute radiation syndrome, including gastrointestinal and hematological types. RxBio has licensed its small-molecule technology from the University of Tennessee Research Foundation.
Products
The lead product of RxBio is Rx100, which is designed to treat gastrointestinal acute radiation syndrome. Rx100 has shown efficacy in multiple animal models and is also being developed to prevent cholera toxin-induced secretory diarrhea and NSAID-induced gastric erosions. The product development has been largely supported by government grants and contracts.
Government Contracts and Support
RxBio has received substantial support from government entities. The company was awarded a contract from the National Institute for Allergy and Infectious Diseases (NIAID) for the accelerated development of medical countermeasures against radiation and nuclear incidents. Additionally, the development of Rx100 has been extensively backed by government grants and contracts, bolstering its research and development efforts.
Strategic Partnerships
RxBio's technology pipeline has been strengthened through strategic partnerships. The company licensed its small-molecule technology from the University of Tennessee Research Foundation, ensuring access to cutting-edge research and development capabilities.